| Document |
Document Title |
|
WO/2016/065142A2 |
Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compo...
|
|
WO/2016/055918A1 |
The present invention relates to novel stable novel stable polymorphs of Isavuconazole or its salt thereof, having purity more than 90 % when measured by HPLC. In particular the present invention directs process for the preparation of so...
|
|
WO/2016/054261A1 |
Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both. Certain compo...
|
|
WO/2016/047533A1 |
The compound represented by formula (1) or a salt thereof has the inhibitory effect of ABA 8'-hydroxylase CYP707A. This compound or a salt thereof can be used as a plant growth regulator. In formula (1), R is a C1-C6 alkyl group, and the...
|
|
WO/2016/046350A1 |
An organic light-emitting element which emits delayed fluorescence comprising specifically substituted 1,2,4-triazole derivatives, 1,2,4-oxadiazole derivatives or 1,2,4-thiadiazole derivatives in the light-emitting layer, a light-emittin...
|
|
WO/2016/041892A1 |
The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel block...
|
|
WO/2016/040084A1 |
Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
|
|
WO/2016/036873A1 |
The present invention relates to compounds of formula (1): The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: Formula (1) wherein R...
|
|
WO/2016/033635A1 |
The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in ...
|
|
WO/2016/033100A1 |
In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting ...
|
|
WO/2016/033023A2 |
A novel quantum-based computational process for drug discovery and design was used to identify potential novel liver-stage anti-malarial therapeutic molecules. The approach combined the latest big-data advances in high-throughput bioassa...
|
|
WO/2016/020403A1 |
The present invention relates to a process for the preparation of a compound of formula (1) wherein the process is based on the use of an organolithium reagent and wherein Ra, Rb, Rc and Rd are, independently of each other, selected from...
|
|
WO/2016/018875A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containi...
|
|
WO/2016/015593A1 |
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or ...
|
|
WO/2016/016370A1 |
The invention pertains to novel FLT3receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.
|
|
WO/2016/005211A1 |
The present invention relates to a process for the preparation of oxirane compounds of formula II from keto compounds III using dimethyl sulfide (CH3)2S and dimethylsulfate (CH3)2SO4,forming the reagent IV, trimethylsulfonium methylsulfa...
|
|
WO/2016/001073A1 |
The invention relates to benzoic acid amides of general formula (I) as herbicides. In formula (I) X, Z and R represent radicals such as alkyl and cycloalkyl. Q represents a 5-membered heterocycle.
|
|
WO/2016/000568A1 |
Disclosed are a compound or crystalline form represented by formula I, pharmaceutically acceptable salts, and hydrate or solvate thereof. R1, R9, and R10 are respectively independently selected from halogen, H, deuterium, non-deuterated ...
|
|
WO/2016/001074A1 |
The invention relates to benzoic acid amides of general formula (I) as herbicides. In formula (I) X, Z and R represent radicals such as alkyl and cycloalkyl. Q represents a 5-membered heterocycle.
|
|
WO/2015/197981A1 |
The invention relates to the probes of formula (I); in which: X1 = NH, O or S; X2 = O or S; SE is a labile group, which may be removed under the action of a stimulus which may in particular be the presence of an enzyme, of a chemical com...
|
|
WO/2015/195950A1 |
The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions c...
|
|
WO/2015/193915A1 |
The present application relates to 1,4-disubstituted 1,2,3-Triazole antifungal agents of the formula (I) wherein, R1 is halogens such as fluorine, chlorine or bromine, CF3, alkyl; R2 is alkyl or hydrogen; R3 is halogen selected from fluo...
|
|
WO/2015/191630A1 |
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
|
|
WO/2015/189035A1 |
The present invention relates to compounds of the formula I wherein the variables are defined in the claims and the specification, and to the preparation and uses of compounds I.
|
|
WO/2015/185708A1 |
The present invention relates to compounds of the formula (I) wherein the variables are defined in the description and claims, their preparation and uses thereof.
|
|
WO/2015/182984A1 |
The present invention relates to a compound containing a self-immolative group. The compound containing a self-immolative group according to the present invention can comprise: a protein (examples: an oligopeptide, a polypeptide, an anti...
|
|
WO/2015/179823A2 |
Described herein are compounds, compositions, and methods of their use treatment of a lung disease.
|
|
WO/2015/173050A1 |
The present invention relates to compounds of the formula (I) wherein the variables are defined in the claims and the specification, to their preparation and their use as fungicides.
|
|
WO/2015/172196A1 |
Novel heterocyclic compounds are provided which display useful efficacy in the treatment of diseases caused by trypanosomatids. Particularly, the compounds of the invention are useful in the treatment of HAT and/or Chagas disease and/or ...
|
|
WO/2015/171930A1 |
Some of the embodiments of the present disclosure relate to a compound of the formula, and methods of preparing and using same.
|
|
WO/2015/167211A1 |
The present invention relates to: a 3-aryl-1,2,4-triazole derivative compound; and a medical use thereof as a preventative and therapeutic agent for diabetes or diabetic complications by using the selective inhibitory activity of the com...
|
|
WO/2015/162558A1 |
The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-med...
|
|
WO/2015/164415A1 |
This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.
|
|
WO/2015/157005A1 |
Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1, N-oxides, and salts thereof, wherein A, Q, R1 and R2 are as defined in the disclosure; and (b) at least one additional f...
|
|
WO/2015/150324A1 |
The present invention relates to organic light emitting elements, comprising thermally activated delayed fluorescence (TADF) emitters and/or hosts on basis of benzotriazoles, which have a sufficiently small energy gap between S1 and T1 (...
|
|
WO/2015/150564A1 |
The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR1 19 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related ...
|
|
WO/2015/150947A1 |
The present invention relates to a process for the preparation of Isavuconazole or its pharmaceutical acceptable salt thereof. In particular aspects of the present invention relates to a process for the preparation of intermediate of azo...
|
|
WO/2015/144480A1 |
The present invention relates to compounds of the formula I, and their use as fungicides, wherein the variables are defined as described in the claims and the specification.
|
|
WO/2015/135984A1 |
The present invention relates to a catalytic method for producing 3-triazolyl-sulfoxide derivatives in enantiomerically pure or in enantiomerically enriched form.
|
|
WO/2015/135438A1 |
The present invention relates to a halogenated sulfur compound such as N-[(1-halogenated)-thiocyclobutyl]-succinimide and preparation method thereof. Disclosed is a catalytic application of such compounds in the reaction of sulfuryl chlo...
|
|
WO/2015/138986A1 |
Novel FXR agonists are disclosed, embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subje...
|
|
WO/2015/132313A1 |
The invention relates to novel heterocyclic compounds, to their use for controlling animal pests, which include arthropods, insects and nematodes, and to methods and intermediate products for producing said novel compounds.
|
|
WO/2015/124932A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L,X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositio...
|
|
WO/2015/120281A1 |
In some aspects, the present invention provides compounds of the formula (IV), wherein the variables are as defined herein, which may be used as inhibitors of histone demethylase or spermine oxidase. Also provided herein are pharmaceutic...
|
|
WO/2015/117912A1 |
Compounds of formula (I), wherein (II) is a five-membered, aromatic ring system which may contain 2 or 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur,and where each ring system may not contain more than ...
|
|
WO/2015/118952A1 |
The present invention provides an epoxy resin composition having excellent storage stability and excellent curability. Specifically, the present invention provides: a compound represented by general formula (I); and an epoxy resin compos...
|
|
WO/2015/116760A1 |
In one aspect, the invention relates to compounds having the formula (I): where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activi...
|
|
WO/2015/115116A1 |
Provided is an organic light emitting element which exhibits stable performance in the atmosphere. This organic light emitting element comprises a positive electrode, a negative electrode and a first organic compound layer that is arrang...
|
|
WO/2015/116786A1 |
In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another asp...
|
|
WO/2015/112014A1 |
The present invention relates to a process comprising the step of reacting a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne, wherein: a (hetero)aryl 1,3-dipole compound is defined as a compound comprising a 1,3-dipole functi...
|
